# SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations

> **NCT05393999** · PHASE2 · WITHDRAWN · sponsor: **Imperial College Healthcare NHS Trust**

## Conditions studied

- SARS-CoV2 Infection
- SARS-CoV-2 Acute Respiratory Disease
- Myeloma
- Leukemia
- Lymphoma
- Immune Thrombocytopenia
- Thrombotic Thrombocytopenic Purpura (TTP)

## Interventions

- **BIOLOGICAL:** BMS-986414
- **BIOLOGICAL:** BMS-986413

## Key facts

- **NCT ID:** NCT05393999
- **Lead sponsor:** Imperial College Healthcare NHS Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-11-29
- **Primary completion:** 2022-03-04
- **Final completion:** 2022-03-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The drug was found to be ineffective against Omicron, so the study was terminated and no patients were enrolled.
- **Last updated:** 2023-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05393999

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05393999, "SABRE: A Single-arm Prospective Study Measuring Safety and Tolerability of SARS-CoV-2 Neutralising Antibodies in High-risk Populations". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05393999. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*